Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.
Matthew Sanders
Advertisement
Matthew Sanders is vice-president, head of Global Drug Substance at GSK, Rixensart, Belgium.
Articles by Matthew Sanders
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
